2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
|
|
- Duane Haynes
- 6 years ago
- Views:
Transcription
1 Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant support: Consultant: DISCLOSURES Gilead, Merck, ViiV Bristol Myers Squibb, Gilead, Janssen, Merck, Teva, ViiV Case 1 34 year old man presents to clinic after having a routine HIV Ab screening test that was positive in a local testing site. He also had a CD4 count sent and was told it was 570 cells/ul The patient was immediately referred to you and is upset but understands that there are good treatments available and he has insurance to cover costs of care, but is nonetheless not completely sure he wants to start treatment He has no past medical history, is asymptomatic, has had 5 different partners of unknown HIV status during the past year, 2 in the last month with inconsistent use of condoms for several years Case 1 Which of the following is closest to what you would recommend to this patient with regards to starting ART? A. Strongly encourage to start B. Recommend he start C. Support him in his wishes to defer D. Other 34 yo asymptomatic man CD4= 570 cells/ul 1
2 START Study Outcomes: Composite Primary Endpoint and its Components Immediate ART superior to deferred ART Serious and non serious AIDS events 68% of the primary endpoints with CD4 >500 cells/mm 3 Similar reductions in events across all subgroups No increase in AEs associated with immediate ART Number of Events Composite Endpoint Number of Serious Events 57% Reduction (P<0.001) AIDS- Related 72% Reduction (P<0.001) Deferred ART (n=2359) Immediate ART (n=2326) 47 Components (Serious Events) 29 Non-AIDS Related 39% Reduction (P=0.04) Lundgren J, et al. 8 th IAS Conference. Vancouver, Abstract MOSY0301. The INSIGHT START Study Group. N Engl J Med. 2015;July 20. [Epub ahead of print]. When to Start ARVs AIDS or HIV-Related CD4 Count (cells/mm 3 ) Symptoms < >500 United States DHHS (2016) Yes Yes Yes Yes Yes IAS-USA (2016) Yes Yes Yes Yes Yes British HIV Association (2016) Yes Yes Yes Yes Yes European AIDS Clinical Society Yes Yes Yes Yes Yes (2016) WHO (2015) Yes Yes Yes Yes Yes DHHS. Revision July 14, Günthard HF, et al. JAMA. 2016;316: EACS. Revision October BHIVA. Revision August WHO. Revision September Case 1 If you and patient decide that starting is the right thing to do, what would you recommend next? A. Send routine laboratory studies, HIV genotype and schedule for f/u appointment when results return B. Send routine laboratory studies without a HIV genotype and start ARVs immediately C. Send routine laboratory studies with a HIV genotype and start ARVs immediately D. Something else 34 yo asymptomatic man CD4= 570 cells/ul 2
3 State-transition Markov process model to assess mortality risk associated with ART delays Patient level data from 3 South African cohorts Estimated increase in mortality from 11 to 14.7% (relative increase of 34%) with a 10- week delay in ART Relative risk similar across CD4 counts but differ for absolute risks Contour Plot 11% 19.7% 24.2% Hoffmann CJ, et al. JAIDS 2013; 63: RCT in South Africa clinics (n=377) SOC had 3 5 additional clinic visits over 2 4 wks prior to ARVs Primary outcome was VL <400 c/ml within 10 months 64 vs. 51%; RR 1.26 (1.05, 1.50) Secondary outcome was initiation ART within 90 days 97 vs. 72%; HR 1.36 (95% CI 1.24, 1.49) New SFGH patients, RAPID era: Indicator RAPID Cohort (n=39) Sociodemographics Universal ART (n=47) P- value Age: mean(range) 32 (21-47) 35 (19-68) NS Male: n (%) % 43 92% NS Non-white ethnicity 23 59% 34 71% NS Homeless 11 28% 13 25% NS Uninsured % % NS Staging Acute (Ab- <6m) 21/30 70% 8/31 26% Log 10 VL 4.9 ( ) 4.5 ( ) NS CD4 mean (range) 474 (3-1391) 417 ( ) NS 3
4 Uptake of same-day ART RAPID era : transmitted resistance and drug regimens Indicator RAPID (n=39) Universal ART (n=47) P Genotype obtained 32/39 (82.1%) 43/47 (91.5%) 0.21 Any 4 8/32 (25.0%) 18/43 (41.9%) 0.13 Major NNRTI-R 4 7/32 (21.9%) 11/43 (25.6%) 0.71 Major PI-R 1/32 (3.1%) 2/43 (4.7%) 0.99 Major NRTI-R 0 (0%) 1/43 (2.3%) 0.99 ART initiated 5,6 39/39 (100%) 38/47 (80.9%) INSTI use 6 35/394 (89.7%) 32/38 (84.2%) 0.47 RAPID Antiretroviral Regimens TDF/FTC + DTG 26 (67%) EVG/COBI/FTC/TDF 7 (18%) TDF/FTC + DRV + RTV 4 (10%) TDF/FTC + RAL 1 ( 2%) ABC/3TC/DTG 1 ( 2%) 4
5 Time to VL suppression by ART initiation strategy: SFGH RAPID Universal ART CD4 guided ART Proportion <200 copies RAPID vs. universal ART P<0.001 Case 1 You encourage him to start on the same day and he agrees. He states that he has no specific concerns regarding adherence, side effects or dosing schedule. Which of the following would you recommend? A. Two NRTIs + boosted PI B. Two NRTIs + RAL C. TDF/FTC/EFV D. TDF (or TAF)/FTC/RPV E. TDF (or TAF)/FTC/COBI/EVG F. TDF (or TAF)/FTC + DTG G. ABC/3TC/DTG H. Something else 34 yo asymptomatic man CD4= 570 cells/ul All laboratory studies are pending Must treat before HIV drug resistance results available Avoid NNRTI based regimens Recommended ART Regimens: DRV/r plus TAF/FTC or TDF/FTC DTG plus TAF/FTC or TDF/FTC Transmitted mutations conferring NNRTI resistance are more likely than mutations with PI or INSTI resistance Resistance to DRV/r and DTG emerges slowly; transmitted resistance to DRV is rare and has not been reported to DTG 5
6 Case 1 You decide to defer therapy pending labs and he now returns: VL 23,000 copies/ml; HBsAb+, HCV Ab-, HLA-B5701 neg, chemistries WNL, Genotype is WT. He is ready to start ARVs and has no specific concerns regarding adherence, side effects or dosing schedule. Which of the following would you recommend? A. Two NRTIs + boosted PI B. Two NRTIs + RAL C. TDF/FTC/FTC/EFV D. TDF (or TAF)/FTC/RPV E. TDF (or TAF)/FTC/COBI/EVG F. TDF (or TAF)/FTC + DTG G. ABC/3TC/DTG H. Other 34 yo asymptomatic man CD4= 570 cells/ul; VL= 23,000 c/ml HLA-B5701-negative CrCl= 90 ml/min HCV-neg; HBsAb+ HIV Genotype- wild type If you chose a tenofovir-based regimen, which would you use? A. TAF B. TDF Case 1 34 yo asymptomatic man CD4= 570 cells/ul; VL= 23,000 c/ml HLA-B5701-negative CrCl= 90 ml/min HCV-neg; HBsAb+ HIV Genotype- wild type Tenofovir Alafenamide (TAF) 90% Lower TFV Levels in Plasma Minimizes Renal and Bone Effects While Maintaining High Potency for Suppressing HIV GI Tract PLASMA HIV TARGET CELL TVF TFV TDF 300 mg TAF 25 mg TFV HIV TFV 6
7 Case 1 (v 2.0) Same patient that you sent off awaiting labs only in this case CD4=145 cells/ul, VL= 180,000 c/ml and he missed several clinic appointments after initial visit. He admits to using alcohol and experiencing mild depression. He has met with psychologist a few times and is relatively stable and drinking some what less. Which of the following would you recommend? A. Two NRTIs + boosted PI B. Two NRTIs + RAL C. TDF (or TAF)/FTC/COBI/EVG D. TDF (or TAF)/FTC + DTG E. ABC/3TC/DTG F. Other 34 yo asymptomatic man using alcohol, depressed and missed visits CD4= 145 cells/ul; VL= 180,000 c/ml HLA-B5701-negative CrCl= 90 ml/min HCV-neg; HBsAb+ HIV Genotype- wild type 7
8 Low Virologic Failure and Treatment- Emergent Resistance With Boosted PIs Trial Name F/u, Wks CASTLE [1] 96 ACTG 5202 [2] 96 Study 103 [3] 144 ARTEMIS [4] 96 FLAMINGO [5] 96 ACTG 5257 [6] 96 Treatment Arm Virologic Failure, n (%) Treatment Emergent Primary Mutations, n ATV/RTV + TDF/FTC (n = 440) 28 (6) 1 (PI), 7 (NRTI) LPV/RTV + TDF/FTC (n = 443) 29 (7) 10 (NRTI) ATV/RTV + NRTIs (n = 928) 140 (15) 1 (PI), 16 (NRTI) EFV + NRTIs (n = 929) 129 (14) 68 (NNRTI), 36 (NRTI) ATV/RTV + TDF/FTC (n = 355) NR (7) 2 (NRTI) EVG/COBI/TDF/FTC (n = 353) NR (8) 8 (INSTI), 8(NRTI) DRV/RTV + TDF/FTC (n = 343) NR (12) 2 (NRTI) LPV/RTV + TDF/FTC (n = 346) NR (17) 5 (NRTI) DRV/RTV + 2 NRTI (n = 242) 4 (2) 0 DTG + 2 NRTI (n = 242) 2 (< 1) 0 ATV/RTV + TDF/FTC (n = 605) 95 (16) 1 (INSTI), 8 (NRTI) DRV/RTV + TDF/FTC (n = 601) 115 (19) 11 (INSTI), 3 (NRTI) RAL + TDF/FTC (n = 603) 85 (14) 1 (INSTI), 7 (NRTI) 1. Molina JM, et al. J Acquir Immune Defic Syndr. 2010;53: Daar ES, et al. Ann Intern Med. 2011;154: Clumeck N, et al. J Acquir Immune Defic Syndr. 2014;65:e121-e Mills A, et al. AIDS. 2009;23: Molina JM, et al. Glasgow HIV Abstract O Lennox JL, et al. Ann Intern Med. 2014;161: Dolutegravir + NRTIs in Treatment- Naive Patients HIV-1 RNA < 50 c/ml by Snapshot Analysis: 95% CI for Treatment Difference SINGLE [1] Favors Favors EFV/TDF/FTC DTG + ABC/3TC FLAMINGO [2] Favors Favors DRV/RTV DTG SPRING-2 [3,4] Favors Favors RAL DTG ARIA [5] Favors Favors ATV+TDF/FTC DTG/ABC/3TC Wk % 7.4% 12.3% 7.1% 0.9% 13.2% 2.5% -2.2% 7.1% 10.5% 3.1% 17.8% Wk % 8.0% 13.8% 12.4% 4.7% 20.2% -1.1% 4.5% 10% Wk % 2% 14.6% -5% 0 15% -12% 0 25% -12% 0 12% -5% 0 20% No resistance selected for in any DTG-containing regimen 1. Walmsley S, et al. J Acquir Immune Defic Syndr. 2015;[Epub ahead of print]. 2. Molina JM, et al. Glasgow HIV Abstract O Raffi F, et al. Lancet. 2013;381: Raffi F, et al. Lancet Infect Dis. 2013;13: Orrell C, et al. IAS Low Virologic Failure and Lack of Treatment-Emergent Resistance With DTG Trial Name F/u, Wks SPRING 2 [1] 96 SINGLE [2] 144 FLAMINGO [3] 96 Study 102 [4] 144 Study 103 [5] 144 Treatment Arm Virologic Failure, n (%) Treatment Emergent Primary Mutations, n DTG + 2 NRTI (n = 411) 22 (5) 0 RAL + 2 NRTIs (n = 411) 29 (7) 1 (INSTI), 4 (NRTI) DTG + ABC/3TC (n = 414) 39 (9) 0 EFV/TDF/FTC (n = 419) 33 (8) 1 (NRTI), 6 (NNRTI) DTG + 2 NRTI (n = 242) 2 (< 1) 0 DRV/RTV + 2 NRTI (n = 242) 4 (2) 0 EVG/COBI/TDF/FTC (n = 348) NR (7) 9 (INSTI), 10 (NRTI) EFV/TDF/FTC (n = 352) NR (10) 4 (NRTI), 14 (NNRTI) EVG/COBI/TDF/FTC (n = 353) NR (8) 8 (INSTI), 8(NRTI) ATV/RTV + TDF/FTC (n = 355) NR (7) 2 (NRTI) 1. Raffi F, et al. Lancet Infect Dis. 2013;13: Pappa K, et al. ICAAC Abstract H-647a. 3. Molina JM, et al. Glasgow HIV Abstract O Wohl DA, et al. J Acquir Immune Defic Syndr. 2014;65:e118-e Clumeck N, et al. J Acquir Immune Defic Syndr. 2014;65:e121-e124. 8
9 Cohort study of all patient starting DTG in two centers in Netherlands N=556; 102 (18.4% naïve); median f/u 225 days 85 (15.3%) stopped DTG; 76 (13.7%) for intolerability De Boer MGJ, et al. AIDS 2016; Case 2 49 year old man with stable DM who had been HIVnegative presents to you for advice regarding how to best avoid HIV infection in his new relationship with an HIV-infected man He states that his partner has been on ARVs for nearly two years with good viral suppression Although they mostly use condoms he had heard that they may not be necessary if his partner is suppressed on ARVs He would rather not use condoms but wants to know what his risks would be without Case 2 Which of the below would be closest to what you would tell him with regards to his risks of acquiring HIV from his current partner if they choose to not use condoms? A. You would be at some risk and should ideally use condoms B. The risk would be very low but can t tell you that it is completely safe C. Your risk under these circumstances is essentially zero 9
10 HPTN 052: Final Results of HIV Prevention in Stable Heterosexual Couples Linked HIV transmission to HIVnegative partner (n=46) Overall 93% reduction in risk of transmission with early therapy Linked partner infections diagnosed after index partner started ART (n=8)* Recently initiated ART (n=4) Virologic failure (n=4) No HIV transmission among people who were suppressed Timing of the linked transmission events supports the model that HIV transmission is very unlikely in the setting of viral suppression Linked Partner Infections (number) Overall *Phylogenetic methods compared HIV pol sequences from index partner pairs and controls. Linkage probability was further assessed by comparing the genetic distances between pol sequences (Bayesian analysis). Cohen M, et al. J Int AIDS Soc. 2015;18(suppl 4):15. Abstract MOAC0101LB. Eshleman SH, et al. J Int AIDS Soc. 2015;18(suppl 4):18. Abstract MOAC0106LB Linked HIV Transmission 36 Delayed ART Early ART Contribution to HPTN 052 Condomless sex MSM Limitatons Power, especially for highest risk MSM Cohort of serodiscordant couples Median duration of condomless sex at entry ~2 years Median duration on suppressive ARVs at entry >7 years Adherence rates >90% Counseled to use condoms Additional lessons High rate of STIs Transmissions from non-regular partners JAMA 2016; 316:
11 Case 2 He and his partner decide, based upon the information you provided him that they would not use condoms as long as the infected partners viral load is undetectable. Then your patient asks you if you would recommend he use PrEP. Which of below would be closest to what you would recommend? A. With an HIV-infected partner it would be appropriate for you to be on PrEP B. Your risk with your current partner on ARVs is too low to justify PrEP C. I would totally leave it up to you D. Something else Case 2 He decides that he wants to use PrEP. He is 4 th generation HIV-negative, HBsAb+, has CrCl- 70 ml/min. Which would be closest to what you would recommend: A. TDF/FTC once daily B. TDF/FTC around sex C. TDF/FTC four times per week D. TDF once daily E. Strongly encourage him not to take PrEP since risk is low and renal function impaired F. Something else Table of Recommendations CDC 1 WHO 2 IAS 3 Population for PrEP MSM or Heterosexual Men and MSM >2% background HIV incidence Women with: Serodiscordant Couples Recent incident STI diagnosis HIV(+) sex partner* Transgender women who Especially syphilis, gonorrhea, or Inconsistent condom use, or have sex with men chlamydia recent STI, or high number of IDU (unless negative partner PEP use >2x in past year sexual partners in serodiscordant IDU who Commercial sex work relationship) Share injection equipment In high prevalence area or Inject 1 times/day network (for heterosexual men Inject cocaine or and women only) methamphetamines IDU HIV(+) injecting partner Sharing injection equipment Recent drug treatment (but currently injecting) Regimen suggested TDF 300 mg + TDF 300 mg + TDF 300 mg + FTC 200 mg FTC 200 mg FTC 200 mg Or Or TDF 300 mg (IDU only) TDF 300 mg (serodiscordant couples only) Timing and Frequency Once Daily Once Daily Once Daily *For any regular sex partner should consider if they are on ARVs with undetectable VL IDU: Injection Drug Users, STI: Sexually Transmitted Infections, MSM: Men Who Have Sex With Men, TDF: Tenofovir, FTC: Emtricitabine, PEP: Post Exposure Prophylaxis, PrEP: Pre Exposure 1 Prophylaxis, CDC: Centers for Disease Control Updated and Prevention, May WHO: 14, World Health Accessed Organization, May 21, IAS: International AIDS Society 2 WHO. Consolidated Guidelines on HIV prevention. Switzerland. July HIV Prevention in Clinical Care Settings Recommendations of the International Antiviral Society USA Panel. July
12 Case 2 Your patient starts TDF/FTC once daily He returns several times over the next 12 months with STIs and ultimately admits that he has sex with multiple men without condoms outside of his current relationship You counsel him to use condoms and he continues to return with frequent STIs but to be repeatedly HIV-negative He is noted during the past year to have a progressive decline in CrCl to approximately 50 ml/min Case 2 The patient is having continued high risk sex despite counseling and has progressive decline in renal function. Which of the below is closest to what you would recommend? A. Continue daily TDF/FTC with close monitoring or renal function B. Tell him it is no longer safe for him to take TDF/FTC so he needs to be more consistent with condom use and PrEP is no longer an option C. Switch to four days per week TDF/FTC D. Switch to TAF/FTC E. Switch to non-tenofovir-based PrEP F. Something else iprex Open Label Extension: HIV Incidence and Drug Concentrations Follow up % 26% 12% 21% 12% Risk Reduction 44% 84% 100% 100% 95% CI 31 to 77% 21 to 99% 86 to 100% (combined) Grant R, et al. 20th IAC; Melbourne, Australia; July 20-25, 2014; Abst. TUAC0105LB; Grant R, et al. Lancet ID. [Epub ahead of print July 22, 2014] iprex Open-Label Extension (iprex OLE). 12
13 Molina JM, et al. 21 st IAC 2016, Abst. WEAC
14 Phase 2 study of safety and tolerability of maraviroc-containing regimens to prevent HIV infection in MSM (HPTN 069/ACTG A5305) 5 incident infections (4 MVC alone, 1 MVC + TDF); no sig difference by regimen. 2 with undetectable drug levels at every visit, 2 low levels at seroconversion visit and 1 variable concentrations Gulick RM, et al. JID 2016 Case 3 56 year old man with long history of HIV, DM, and CAD. He has been followed off ARV for several years and now finally agrees to start. No symptoms and negative exam with bp- 125/75 CD4 335 cells/ul; VL 120,000 copies/ml HLA-B5701-negative HgbA1C 7.1% on metformin 1000 mg bid HBVsAb+, HCV Ab- UA with 2+ protein, CrCl 47 ml/min HIV genotype is WT Case 3 Which of the following would you recommend? A. TAF/FTC/EVG/COBI B. TAF/FTC + RAL C. TAF/FTC + boosted PI D. TAF/FTC + DTG E. ABC/3TC/DTG F. ABC/3TC + boosted PI G. ABC and TAF-sparing regimen H. Something else 56 yo man with chronic HIV, DM, CAD CD4 335 cells/ul; VL- 120,000 c/ml HLA-B5701-negative CrCl= 47 ml/min, UA 2+ proteinuria HgbA1C- 7.1% on metformin 1000 mg bid HCV-neg; HBsAb+ Genotype- WT 14
15 Case 3 Which of the following would you recommend if the same patient started out with relatively normal renal function but experienced a decline while on a stable suppressive regimen of TDF/FTC + RAL? A. Monitor without change B. TAF/FTC-based regimen C. ABC/3TC-based regimen D. ABC and TAF-sparing regimen E. Something else 56 yo man with chronic HIV, DM, CAD VL suppressed on TDF/FTC + RAL HLA-B5701-negative CrCl= 47 ml/min, UA 2+ proteinuria Baseline Genotype- WT Abacavir and Cardiovascular Events Study Association Description D:A:D [1] + Cohort collaboration (prospective) Danish HIV Cohort [2] + Cohort (linked with registries) Montreal study [3] + Nested case-control study SMART [4] + Post hoc subgroup analysis of RCT (use of ABC not randomized) STEAL [5] + Preplanned secondary analysis of RCT (use of ABC randomized) Swiss HIV Cohort [6] + Cohort (retrospective) FHDH ANRS CO4 [7] Equivocal Nested case-control study NA-ACCORD [8] Equivocal Cohort (retrospective) VA Clinical Case - Cohort (retrospective) Registry [9] Brothers et al analysis [10] - Post hoc meta-analysis of RCTs ACTG A5001/ALLRT [11] - Post hoc meta-analysis of RCTs FDA meta-analysis [12] - Post hoc meta-analysis of RCTs 1. Friis-Møller N, et al. N Engl J Med. 2003;349: Obel N, et al. HIV Med. 2010;11: Durand M, et al. J Acquir Immune Defic Syndr. 2011;57: Phillips AN, et al. Antiviral Ther. 2008;13: Martin A, et al. AIDS. 2010;24: Young J, et al. J Acquir Immune Defic Syndr. 2015;[Epub ahead of print]. 7. Lang S, et al. AIDS. 2010;24: Palella F, et al. CROI Abstract 749LB. 9. Bedimo RJ, et al. Clin Infect Dis. 2011;53: Brothers CH, et al. J Acquir Immune Defic Syndr. 2009;51: Ribaudo HJ, et al. Clin Infect Dis. 2011;52: Ding X, et al. J Acquir Immune Defic Syndr. 2012;61: GS-112: Switching to a TAF-Based Regimen in Pts With Renal Impairment Virologically suppressed, HIVpositive pts with mildmoderate renal impairment (stable egfr CG [30-69 ml/min]) (N = 242) Multicenter, open-label phase III trial TDF-Based ART (n = 158) Non-TDF Based ART (n = 84) Wk 24 Wk 48 EVG/COBI/FTC/TAF (N = 242) Wk 96 ART use,% PI NNRTI INSTI CCR5 Antag. TDF ABC Other NRTI No NRTI Gupta S, et al. IAS Abstract TUAB
16 GS-112: Key Results Change in egfr From Baseline to Wk 48 Median Change From Baseline 10 0 TDF Non-TDF * -10 Baseline: *P <.05 egfr CG ml/min egfr CKD-EPI Cr ml/min/1.73 m 2 Actual GFR by Iohexol Clearance From Baseline to Wk 24 Iohexol Clearance (ml/min) 80 TDF Non-TDF GLSM Ratio vs BL (% [90% CI]): BL Wk 2/4/8 Wk (94-102)(96-105) BL Wk 2/4/8 96 (86-108) Wk (87-111) Gupta S, et al. IAS Abstract TUAB0103. Case 3 If you were going to go with ABC and TAF-sparing regimen, which of the following would you recommend? A. Boosted PI alone B. Boosted PI + 3TC C. Boosted PI + INSTI D. Boosted PI + NNRTI E. DTG alone F. DTG + 3TC G. DTG + RPV H. Something else 56 yo man with chronic HIV, DM, CAD CD4 335 cells/ul; VL- 120,000 c/ml HLA-B5701-negative CrCl= 47 ml/min, UA 2+ proteinuria HgbA1C- 7.1% on metformin 1000 mg bid HCV-neg; HBsAb+ Genotype- WT NEAT: RAL + DRV/RTV vs. TDF/FTC + DRV/RTV in Naive Pts at 96 Wks Randomized, open-label phase III study of DRV/RTV + RAL vs DRV/RTV + TDF/FTC in ART-naive pts Primary Endpoint at Wk 96: Adjusted Difference Estimate (95% CI) RAL - TDF/FTC RAL TDF/FTC Overall N = BL HIV-1 RNA < 100,000 c/ml n = ,000 c/ml n = 275 BL CD4+ cell count < 200/mm n = /mm n = Raffi F, et al. Lancet 2014; 384: (P =.09) (P =.02) 16
17 Simplification to RTV-Sparing and/or NRTI-Sparing or NRTI-Limiting Regimens (partial list) Study N Switch Regimen Results ASSURE [1] 296 ATV + ABC/3TC Similar efficacy as continued standard ART; decline in urine β 2 -microglobulin creatinine ratio OLE [2] 250 LPV/RTV + 3TC Similar efficacy as continued standard ART or FTC NA [3] 48 DRV/RTV + 3TC Small study; encouraging efficacy ATLAS-M [4] 266 ATV/RTV + 3TC Improved efficacy vs ATV/RTV + 2 NRTIs SALT [5] 286 ATV/RTV + 3TC Similar efficacy as continued standard ART KITE [6] 60 LPV/RTV + RAL Small study; encouraging efficacy 1. Wohl DA, et al. HIV Med. 2016;17: Arribas JR, et al. Lancet Infect Dis. 2015;15: Casado JL, et al. J Antimicrob Chemother. 2015;70: Di Giambenedetto S, et al. EACS Abstract Perez-Molina JA, et al. Lancet Infect Dis. 2015;15: Ofotokun I, et al. AIDS Res Hum Retroviruses. 2012;28:
18 Thank You!! 18
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationHIV Treatment Update 8/3/2015. When to Start. Disclosures
8/3/215 HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationJoseph Cofrancesco Jr, MD, MPH, FACP
Friday Case Series Joseph Cofrancesco Jr, MD, MPH, FACP Associate Professor of Medicine Director and Johns Hopkins Institute for Excellence in Education Professor of Medicine Join us on Facebook Follow
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More informationCase Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016
Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationIAS 2015: Return to Vancouver
IAS 2015: Return to Vancouver Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School NEAETC Memories from 1996 First
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationTUESDAY AM HIV DISCUSSION SERIES. 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D.
TUESDAY AM HIV DISCUSSION SERIES 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D. HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D. The Art of HAART
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More information5/2/2016. Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion
Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion Joseph J. Eron, Jr, MD Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina FORMATTED: 4/13/216
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationClinical considerations in switching antiretroviral therapy
Clinical considerations in switching antiretroviral therapy David Jilich Department of Infctious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital 4th CEE Meeting
More informationWhen PrEP fails. Laura Waters MD FRCP Mortimer Market Centre London
When PrEP fails Laura Waters MD FRCP Mortimer Market Centre London www.aidsunited.org PrEP works If people at risk take it If it s taken in the right way If it s available Commissioned/licensed Affordable
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationSlide #1 Case Presentation: Kidney Disease
Slide #1 Case Presentation: Kidney Disease Christina Wyatt, MD Mount Sinai, New York Slide #2 Disclosures Investigator-initiated research support Gilead Sciences Honoraria for internal education Bristol
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationFaculty. Robert LoNigro, MD, MS SVP and Chief Clinical Officer Envolve PeopleCare Austin, TX
Learning Objectives Investigate the impact of antiretroviral therapy selection on factors that influence therapeutic effectiveness in patients with HIV, such as adherence, drug resistance, and safety.
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationFaculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationStatistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University
Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationAntiretroviral Therapy: When and What to Start. Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine
Antiretroviral Therapy: When and What to Start Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine Learning Objectives As a results of participating in this activity participants
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationRapid ART Program Initiative: How immediate ART initiation improves health outcomes
SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH Rapid ART Program Initiative: How immediate ART initiation improves health outcomes Earlier treatment is better care 1,2 START: HIV+ adults who started ART immediately
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationPrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationHIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic
HIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic Yes No What s Going on Out There? Condomless Sex among
More informationAntiretroviral Therapy in Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy in 2013 Joel Gallant, MD, MPH Johns Hopkins University School of Medicine When to Start When to Start: DHHS Guidelines, February 2013 ART recommended for all HIV+ individuals to
More information